WO2006102964A3 - Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release - Google Patents

Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release Download PDF

Info

Publication number
WO2006102964A3
WO2006102964A3 PCT/EP2006/001948 EP2006001948W WO2006102964A3 WO 2006102964 A3 WO2006102964 A3 WO 2006102964A3 EP 2006001948 W EP2006001948 W EP 2006001948W WO 2006102964 A3 WO2006102964 A3 WO 2006102964A3
Authority
WO
WIPO (PCT)
Prior art keywords
weight
substance
pellets
active ingredient
pharmaceutical form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/001948
Other languages
French (fr)
Other versions
WO2006102964A2 (en
Inventor
Hans-Ulrich Petereit
Rosario Lizio
Hema Ravishankar
Ashwini Samel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roehm GmbH Darmstadt
Original Assignee
Roehm GmbH Darmstadt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roehm GmbH Darmstadt filed Critical Roehm GmbH Darmstadt
Priority to CA002600282A priority Critical patent/CA2600282A1/en
Priority to JP2008503388A priority patent/JP2008534530A/en
Priority to BRPI0609598-4A priority patent/BRPI0609598A2/en
Priority to EP06723192A priority patent/EP1863453A2/en
Priority to US11/816,372 priority patent/US20080220080A1/en
Priority to CN200680003450XA priority patent/CN101111230B/en
Publication of WO2006102964A2 publication Critical patent/WO2006102964A2/en
Publication of WO2006102964A3 publication Critical patent/WO2006102964A3/en
Priority to IL186269A priority patent/IL186269A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a multiparticulate pharmaceutical form, comprising pellets with a multilayer structure for controlled active ingredient release, comprising a) a core layer comprising a substance having a modulating effect, b) an inner controlling layer which influences the delivery of the substance having a modulating effect, consisting of pharmaceutically usable polymers, waxes, resins and/or proteins, c) an active ingredient layer comprising an active pharmaceutical ingredient and, where appropriate, a substance having a modulating effect, d) an outer controlling layer comprising at least 60% by weight of one or a mixture of a plurality of (meth) acrylate copolymers where the layers may additionally and in a manner known per se comprise pharmaceutically usual excipients, where the outer controlling layer d) has a thickness from 20 to less than 55 µm and contains 0,1 to 10% by weight of glycerol monostearate, where the multiparticulate pharmaceutical form contains 20 to 60% by weight of the pellets, which are compressed in mixture with 80 to 40% by weight of an outer phase which consists from 50 to 100% by weight of a cellulose or a derivate of cellulose and optionally 0 to 50% by weight of further pharmaceutical excipients .
PCT/EP2006/001948 2005-03-29 2006-03-03 Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release Ceased WO2006102964A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002600282A CA2600282A1 (en) 2005-03-29 2006-03-03 Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
JP2008503388A JP2008534530A (en) 2005-03-29 2006-03-03 Multiparticulate drug form containing pellets with a substance having a modulating effect on active ingredient release
BRPI0609598-4A BRPI0609598A2 (en) 2005-03-29 2006-03-03 multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect with respect to active ingredient release
EP06723192A EP1863453A2 (en) 2005-03-29 2006-03-03 Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
US11/816,372 US20080220080A1 (en) 2005-03-29 2006-03-03 Multiparticulate Pharmaceutical form Comprising Pellets with a Substance Having a Modular Effect in Relation to Active Ingredient Release
CN200680003450XA CN101111230B (en) 2005-03-29 2006-03-03 Multiparticulate pharmaceutical form comprising pellets with modified release of active ingredient
IL186269A IL186269A0 (en) 2005-03-29 2007-09-25 Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN324CH2005 2005-03-29
IN324/CHE/2005 2005-03-29

Publications (2)

Publication Number Publication Date
WO2006102964A2 WO2006102964A2 (en) 2006-10-05
WO2006102964A3 true WO2006102964A3 (en) 2007-03-29

Family

ID=37053736

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/001948 Ceased WO2006102964A2 (en) 2005-03-29 2006-03-03 Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release

Country Status (8)

Country Link
US (1) US20080220080A1 (en)
EP (1) EP1863453A2 (en)
JP (1) JP2008534530A (en)
CN (1) CN101111230B (en)
BR (1) BRPI0609598A2 (en)
CA (1) CA2600282A1 (en)
IL (1) IL186269A0 (en)
WO (1) WO2006102964A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9205048B2 (en) 2008-07-21 2015-12-08 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US9486405B2 (en) 2013-08-27 2016-11-08 Otonomy, Inc. Methods for the treatment of pediatric otic disorders
US11123286B2 (en) 2008-04-21 2021-09-21 Otonomy, Inc. Auris formulations for treating otic diseases and conditions

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116728B2 (en) 2006-11-30 2021-09-14 Bend Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
US10357462B2 (en) 2006-11-30 2019-07-23 Ben Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
WO2008068778A2 (en) * 2006-12-05 2008-06-12 Alembic Limited Extended release pharmaceutical composition of pramipexole
HU227881B1 (en) * 2007-02-23 2012-05-29 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sustained release pharmaceutical preparation containing carvedilol
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
AU2008286914B2 (en) * 2007-08-13 2014-10-02 Ohemo Life Sciences Inc. Abuse resistant drugs, method of use and method of making
US9011907B2 (en) * 2008-01-10 2015-04-21 Evonik Röhm Gmbh Coated pharmaceutical or nutraceutical preparation with enhanced pulsed active substance release
DE102008004893A1 (en) * 2008-01-17 2009-07-23 Add Technologies Ltd. Carrier pellets, process for their preparation and their use
US8030297B2 (en) 2008-05-14 2011-10-04 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders
CA2741038C (en) * 2008-11-18 2015-01-13 Ucb Pharma S.A. Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
EP2358360B1 (en) * 2008-11-18 2016-09-14 UCB Biopharma SPRL Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative
KR101004205B1 (en) * 2008-12-17 2010-12-24 동아제약주식회사 Controlled Release Compositions for Preparing Udenafil-Containing Sustained-Release Formulations
WO2011082426A1 (en) * 2010-01-04 2011-07-07 Eurand, Inc. Controlled release compositions comprising meclizine or related piperazine derivatives
US9492394B2 (en) * 2010-08-18 2016-11-15 Evonik Roehm Gmbh Gastric resistant pharmaceutical or nutraceutical formulation comprising one or more salts of alginic acid
CN102727452B (en) * 2011-04-01 2014-12-24 成都康弘药业集团股份有限公司 Eszopiclone-containing particle and its preparation method
US10624847B2 (en) * 2011-08-02 2020-04-21 AnPac BioMedical Science Co., Ltd. Decomposable apparatus and methods for fabricating same
WO2013047795A1 (en) * 2011-09-30 2013-04-04 アステラス製薬株式会社 Granular pharmaceutical composition
TWI643613B (en) * 2012-08-03 2018-12-11 安派科生物醫學科技有限公司 Degradable instrument
WO2016042565A1 (en) * 2014-09-16 2016-03-24 Suresh Pareek Extended release 'formulation of metoprolol
GB201607548D0 (en) * 2016-04-29 2016-06-15 Univ Central Lancashire Solid dosage form
JP6739275B2 (en) * 2016-08-02 2020-08-12 日本化薬株式会社 Pharmaceutical composition containing gefitinib as an active ingredient
JP6957610B2 (en) * 2016-10-06 2021-11-02 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ Multilayer beads for pharmaceutical use
EP3459528B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
JP7761403B2 (en) * 2020-05-14 2025-10-28 沢井製薬株式会社 Water-insoluble polymer-coated granules, preparations containing the same, orally disintegrating tablets, and methods for producing the same
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
US12409145B2 (en) * 2020-09-10 2025-09-09 Sawai Pharmaceutical Co., Ltd. Granule, preparation containing the granule, production method of the granule, and production method of preparation containing the granule
CN114376983B (en) * 2021-12-16 2023-08-29 中科清风康健医学研究(北京)有限公司 Natural extract composite granule suitable for high uric acid population
CN114796155B (en) * 2022-03-31 2023-06-27 诺丁汉大学卓越灯塔计划(宁波)创新研究院 Natural active substance-zein nano-particles and preparation method and application thereof
CN116686827B (en) * 2023-08-04 2023-10-31 山东科大创业生物有限公司 Particle structure with multiple membranes and multiple release for prolonging efficacy duration, preparation method and application
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956486A1 (en) * 1999-11-24 2001-06-21 Lohmann Therapie Syst Lts Multi-layer preparation for the controlled, pulsed delivery of active ingredients
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
EP1213015A1 (en) * 1995-07-05 2002-06-12 Byk Gulden Lomberg Chemische Fabrik GmbH Oral pharmaceutical composition with delayed release of proton pump inhibitors
WO2002060415A1 (en) * 2001-01-31 2002-08-08 Röhm GmbH & Co. KG Multi-particulate form of medicament, comprising at least two differently coated forms of pellet

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
JPH0710745A (en) * 1993-06-22 1995-01-13 Tanabe Seiyaku Co Ltd Release-controlled intestinal delivery oral formulation
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
MXPA01004381A (en) * 1998-11-02 2005-09-08 Elan Corp Plc Multiparticulate modified release composition.
DE10149674A1 (en) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orally administered composition for sustained release of propiverine, useful for treatment of hypertonic bladder disorders, especially by once-daily administration
DE10353186A1 (en) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Multilayer dosage form containing a modulatory substance in relation to the release of active ingredient
DE10353196A1 (en) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Multilayer dosage form with a matrix influencing the delivery of a modulatory substance

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1213015A1 (en) * 1995-07-05 2002-06-12 Byk Gulden Lomberg Chemische Fabrik GmbH Oral pharmaceutical composition with delayed release of proton pump inhibitors
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
DE19956486A1 (en) * 1999-11-24 2001-06-21 Lohmann Therapie Syst Lts Multi-layer preparation for the controlled, pulsed delivery of active ingredients
WO2002060415A1 (en) * 2001-01-31 2002-08-08 Röhm GmbH & Co. KG Multi-particulate form of medicament, comprising at least two differently coated forms of pellet

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11123286B2 (en) 2008-04-21 2021-09-21 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US9205048B2 (en) 2008-07-21 2015-12-08 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US9233068B2 (en) 2008-07-21 2016-01-12 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders
US9486405B2 (en) 2013-08-27 2016-11-08 Otonomy, Inc. Methods for the treatment of pediatric otic disorders

Also Published As

Publication number Publication date
US20080220080A1 (en) 2008-09-11
JP2008534530A (en) 2008-08-28
IL186269A0 (en) 2008-01-20
CN101111230A (en) 2008-01-23
CN101111230B (en) 2010-05-19
CA2600282A1 (en) 2006-10-05
BRPI0609598A2 (en) 2010-04-20
EP1863453A2 (en) 2007-12-12
WO2006102964A2 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
WO2006102964A3 (en) Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
WO2005046561A3 (en) Multilayer dosage form comprising a matrix that influences release of a modulatory substance
WO2008142627A3 (en) Multilayered modified release formulation comprising amoxicillin and clavulanate
WO2009090670A3 (en) Stabilized sustained release composition of bupropion hydrochloride and process for preparing the same
WO2009028891A3 (en) 1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same
WO2006039499A3 (en) Method for improving the biovailability of orally delivered therapeutics
WO2005046649A3 (en) Multilayer pharmaceutical dosage form containing a substance that acts in a modulatory manner with regard to the release of active substances
WO2007090882A3 (en) Pharmaceutical extended release compositions comprising pramipexole
WO2004062577A3 (en) Two or more enteric materials to regulate drug release
WO2010057118A3 (en) Heterocyclic antagonists of prostaglandin d2 receptors
WO2010003127A3 (en) Antagonists of prostaglandin d2 receptors
WO2010037059A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
WO2005070462A3 (en) Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
WO2009145989A3 (en) Aminoalkylphenyl antagonists of prostaglandin d2 receptors
WO2009034541A3 (en) Controlled release pharmaceutical dosage forms of trimetazidine
EP1614413A3 (en) Solid dosage form for acid-labile active ingredient
WO2011077451A3 (en) Controlled release pharmaceutical composition
WO2004030652A3 (en) Dosage form having an inner core and at least two coating layers
WO2008013757A3 (en) Delivery system and method of manufacturing the same
EP2420232A3 (en) Angiotensin II receptor antagonist for the prevention or treatment of cardiovascular diseases in cats
WO2003057150A3 (en) A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2006123364A3 (en) Oral drug delivery system providing a coating comprising both a cellulose and a methacrylic acid derivative
WO2003096874A3 (en) Coated sustained release tablets of a hygroscopic compound for once-a-day therapy

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006723192

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200680003450.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 11816372

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/A/2007/010610

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2600282

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 186269

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008503388

Country of ref document: JP

Ref document number: 4305/CHENP/2007

Country of ref document: IN

Ref document number: 1020077022257

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWP Wipo information: published in national office

Ref document number: 2006723192

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0609598

Country of ref document: BR

Kind code of ref document: A2